Unimpeded Growth of Tumour in Hosts Pre-immunized with Tyrosyl- or Dinitrophenyl-coated Tumour Cells by Bauminger, Sara & Yachnin, Stanley
Br. J. Cancer (1972) 26, 77
UNIMPEDED GROWTH OF TUMOUR IN HOSTS PRE-IMMUNIZED
WITH TYROSYL- OR DINITROPHENYL-COATED
TUMOUR CELLS
SARA BAUMINGER* AND STANLEY YACHNINt
Received for publication January 1972
Summary.-Techniques are described for hapten attachment to the cell membranes
of mouse tumour cells. Dinitrophenylation and tyrosylation could be achieved
without substantial loss of viability as measured by dye exclusion. In addition
hapten coated tumour cells were capable of initiating new tumour formation in
syngeneic hosts. Pre-immunization of recipient mice with hapten coated tumour
cells did not increase their resistance to tumour formation upon subsequent chal-
lenge with graded doses of untreated tumour cells.
REJECTION of tumours is due in part
to the ability of the host to react to
tumour-specific transplantation antigens
(TSTA) present in the tumour cell mem-
brane. The immunogenicity of many
antigens depends upon the co-operative
interaction of two immunologically com-
petent cells with the antigen, each at the
site of a different antigenic determinant
on the antigen molecule, commonly
referred to as " carrier " and " haptenic "
sites. If TSTA differ from host cell
surface antigens by only a single, or a
restricted number of antigenic determi-
nants, cellular synergy, which has been
demonstrated for cellular immunity as
well as for humoral antibody response,
may not be possible. Under such circum-
stances, introduction of other antigenic
determinants into the tumour cell mem-
brane may enhance the ability of the
host to mount an immune response
against the tumour cell. A variety of
experimental observations suggest that
such a mechanism may indeed result in
increased resistance to in vivo tumour
cell growth. The theoretical framework
for the role of cell co-operation in tumour
immunity, and speculations on manipula-
tions that might enhance tumour rejec-
tion have been presented by Mitchison
(1970).
The present investigation was under-
taken to study whether or not the
immunogenicity of a murine leukaemia
cell could be enhanced by the exogenous
introduction of dinitrophenyl (DNP) or
tyrosyl (TYR) groups on to the tumour
cell membrane. In view of the ability of
excess hapten groups to interfere with
immune responses to certain tumour cells
(Wolf, Parry and Barfoot, 1970), particular
attention was paid to the details of the
procedures for hapten attachment.
Tumour cells were reacted with hapten
so that viability as measured by trypan
blue exclusion was not affected and a
substantial proportion of cells were still
able to initiate tumour formation.
MATERIALS AND METHODS
Mice
CBA male mice between the ages of 10
and 16 weeks were used in all studies.
Tumour ce1ls
Gross passage A virus-induced leukaemia
was initiated in newborn male CBA mice,
and the leukaemic cells were adapted to
growth as solid tumours in the subcutaneous
tissue ofadult male CBA mice. Cells derived
from the 3-5 subcutaneous passage of the
tumour were used in the experiments to be
described.
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To obtain tumour cell suspensions, mice
bearing subcutaneous tumour masses were
killed by cervical dislocation, and the tumour
masses were dissected free of surrounding
tissue. Single cell suspensions were prepared
by mincing the tumour tissue with stainless
steel scissors, gently pressing the minced
tissue through nylon mesh, and filtering the
resultant cell suspension through ethanol
washed (and dried) cotton wool. This
removed cell clumps and tissue fragments
as well as many of the non-viable cells as
measured by trypan blue dye exclusion.
All the above procedures were performed in
cold (0-4' C) Gey's solution, pH 7-4.
Dinitrophenylation of tumour cells
Twenty-five ,ul of dinitrofluorobenzene
(DNFB) were dissolved in 0 5 ml dimethyl-
sulfoxide (DMSO). This solution was then
added drop-wise at room temperature to
50 ml Gey's solution previously adjusted to
pH 8-4 with IN NaOH. The absorbency of
this DNFB solution was measured at 360 nm
and was adjusted to 0 940 yielding a DNFB
solution containing 10 jug/ml (0.54 mmol/l.).
This DNFB solution or an appropriate
dilution thereof (see below) was used without
delay for the dinitrophenylation of tumour
cells. Tumour cell suspensions at a con-
centration of 50 x 106/ml were prepared in
Gey's solution, pH 8-4, and warmed to
30°C in a water bath. One-fortieth volumes
of DNFB solution were added; final con-
centrations of DNFB during exposure to
tumour cells varied from 0-25-0-0025 ,ug
DNFB/ml except where noted. Following
2 min incubation at 30°C the cell suspensions
were poured into 10 volumes Gey's solution
pH 7.4, 0C, and washed 4 times. They
were suspended in the same medium and
adjusted to appropriate concentration for
viability testing and inoculation.
Tyrosylation of tumour cells
Tyrosylation of tumour cells was per-
formed according to the method described
by Rimon and Sela (1966) for attachment of
tyrosyl determinants to erythrocytes.
Tumour cell suspensions at a concentration
of 4 x 106 cells/ml were prepared in phos-
phate buffer 0-06 mol/l, pH 7 0, at 40C.
Twenty p1 of absolute dioxane containing
40 or 400 Mug of N-carboxy-L-tyrosine
anhydride (1 or 10 mg/108 cells), was added
with stirring. The suspensions was stirred
1 hour at 4°C, centrifuged, washed 4 times
with the same buffer and resuspended in
Gey's solution.
Assessment of number of DNP sites on tumour
cells
An appropriate dilution of rabbit anti-
DNP antiserum (0.25 ml) was incubated
with varying numbers of DNFB-treated
tumour cells for 30 min at 40C. The cells
were then removed by centrifugation and
the amount of antigen binding capacity
(ABC) remaining was determined by a
modified Farr assay (Brownstone, Mitchison
and Pitt-Rivers, 1966) using 0'25 ml of the
supernatant. The dilution of anti-serum
initially chosen was one-half that requiredto
bind 50%0 of the radioactive antigen in the
Farr assay. Since the slope of binding of
the anti-DNP antibody by non-radioactive
hapten was different from that displayed by
DNP tumour cells, the amount of DNP
bound to tumour cells was expressed as the
concentration of cells in the original cell
suspension required to absorb 5000 of the
ABC of the anti-DNP antibody. Untreated
tumour cells or DMSO-treated cells did not
alter the ABC of the antiserum.
Assessment of number of TYR sites on tumour
cells
The polytyrosyl cells were tested for
agglutination by rabbit antiserum against
poly-L-tyrosyl gelatin, prepared as described
by Sela and Arnon (1960). This antiserum
contained about 0 5 mg antibody directed
against poly-L-tyrosyl determinants. The
reaction was performed by mixing 0-2 ml
of serial dilutions of the antiserum with
0-1 ml of cell suspension (1 x 107/ml),
followed by incubation for one hour at
37°C and overnight at 40C. Untreated
tumour cells were used as controls. Normal
rabbit serum did not cause agglutination.
Antigenic structure of tyrosylated cells
An antiglobulin test was performed in
order to study the presence of H2 antigens
on control and tyrosylated tumour cells.
This was done using the isotopic antiglobulin
technique described by Beverley and Simpson
(1970). An anti-CBA serum (a gift from
Dr Peter Beverley) at 1/4 and 1/16 dilution
was used, with a cell concentration of 20
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million per ml. The results are expressed
as absorption ratio; e.g. counts with anti-
CBA serum: counts with normal serum at
the same dilution.
DNFB skin painting
The clipped abdominal skin of mice was
painted with 50 pl of a 0-5% solution (v/v)
of DNFB in 50% olive oil-50% acetone 3
times at weekly intervals. One week later
these mice were immunized with x-ray-killed
control or DNFB-coated tumour cells.
DNP6 CGG immunization
Mice were immunized with 100 ,ug alum-
precipitated DNP-chicken y-globulin (DNP6
CGG) using 2 x 109 pertussis organisms as
adjuvant. Three weeks later they were
immunized with x-ray-killed tumour cells.
Assessment of the effect of hapten attachment
on growth of tumour cells
Mice were injected with graded doses of
control or hapten-coated tumour cells, and
the presence oftumours was established after
8 weeks (see below).
The effect of pre-immunization with hapten
coated tumour cells on subsequent tumour
growth
DNP.-Control, DNFB skin-painted, and
DNP6 CGG-immunized mice were injected
intraperitoneally with 107 x-ray-killed (5000
rad in vitro, 60Co source) untreated, or
DNFB-treated tumour cells. Ten days later
they were challenged with graded doses of
tumour cells injected in 0-2 ml volumes
s.c. in the right flank. The animals were
examined for tumour masses at weekly
intervals by palpation, and the results
reported are those obtained 8 weeks after
challenge, since mice that did not have
tumour masses by that time never developed
tumours subsequently. No attempt was
made to grade tumour size.
TYR.-Mice were immunized with 106
irradiated control or TYR tumour cells
intraperitoneally. They were boosted 10
days later with 107 irradiated cells intra-
peritoneally, and challenged with s.c. injec-
tions of graded doses of tumour cells 10 days
after the last immunization.
Viability of DNFB-coated spleen cells
In order to assess the effect of DNFB
exposure on the viability of normal cells
the following experiment was performed:
a suspension of spleen cells free of con-
taminating RBC was prepared by NH4C1
lysis of RBC. The spleen cells were treated
with DNFB as described earlier, and their
ability to protect lethally irradiated mice
(900 rad) from death was compared with
that of normal spleen cells.
Viability of cells by trypan blue dye exclusion
Equal volumes of cells in Gey's solution
and trypan blue (0.16% in saline) were
mixed, and the proportion of cells excluding
dye was determined microscopically.
RESULTS
Varying numbers of tumour cells from
the third tumour passage were tested for
their efficacy in establishing subcutaneous
tumours. The number of viable tumour
cells required to establish tumours in
5000 of recipient mice was between 103
and 104 cells (Table I).
Exposure of tumour cells to varying
concentrations of DNFB for 2 min at
30°C established that viability, as
measured by trypan blue dye exclusion,
was substantially diminished by concen-
trations of DNFB in excess of 0-25 pg/ml.
TABLE I.-TumourFormation by Untreated
Tumour Cells Injected s.c.
Viable number of Recipients with tumours
tumour cells injected (%)
103 35-1 (59/168)*
104 88-0 (119/134)
* Number of tumours observed/number of
animals in group.
TABLE II.-Effect of DNFB Exposure on
Trypan Blue Viability of Tumour Cells
Trypan blue
viability (%o)
Trypan blue
viability (%) . 93
Experiment I
Concentration of DNFB
( ±g/ml)
0 10 5 1 0 5 0-25
91 15 11 20 58 71
Experiment II
Concentration of DNFB
(fg/ml)
0 0 25 0 025 00025
73 82-5 84-5
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Lesser concentrations of DNFB had little
or no effect upon cell viability (Table II).
The ability of DNFB-treated tumour cells
to induce subcutaneous tumours was
reduced to approximately 1/100 of control
values when concentrations of 0-25 ,ug/ml
DNFB were utilized; exposure of tumour
cells to 0-025 ,tg/ml DNFB had little or
no discernible effect upon their ability
to generate tumours (Table III). In
number of DNP sites on spleen cells so
treated, as well as residual viability as
assessed by trypan blue dye exclusion,
were similar to those of tumour cells
exposed to DNFB under the same condi-
tions.
Exposure of tumour cells to 0-25,
0-025, or 0-0025 ,ug/ml DNFB and subse-
quent immunoassay of the number of
TABLE III.-Tumour Formation by Control
and DNFB-treated Tumour Cells
Number
of cells
injected
107
106
105
104
103
Control
N.D.*
N.D.
8/8t
4/6
1/8
DNFB
0* 25 ,ug/ml
7/8
0/8
0/6
N.D.
N.D.
DNFB
0-025 ,ug/ml
8/8
8/8
5/8
6/9
N.D.
* N.D. = not done.
t Number of tumours observed
Number of animals injected'
TABLE IV.-Effect of DNFB Treatment
of Spleen Cells on Viability of Haemato-
poietic Stem Cells
Number
of cells
injected
i.V.
40 x 106
20x 106
4x 106
Number of mice surviving 10 days
following 900 rad whole body
irradiation*
Control DNFB DNFB
spleen spleen cells spleen cells
cells (0-25 [ig/ml) (0-025 ,ug/ml)
5/5t 0/5 5/5
5/5 0/5 5/5
4/5 0/5 5/5
* 0/9 animals receiving no cells were alive 10
days post-irradiation.
t Number of animals surviving
Number of animals in group
E
O 106-
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0
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FIG. 1.-Estimation of the amount of DNP
on tumour cells exposed to varying con-
centrations of DNFB. The figures in
parentheses represent the concentration
of DNFB-treated cells required to yield
50% inhibition of the antigen-binding
capacity (ABC) of the anti-DNP anti-
serum.
order to compare the effects of tumour
cell exposure to DNFB on cell viability
with normal cells similarly treated, mouse
spleen cells were treated with DNFB,
0-25 and 0-025 /tg/ml, and then tested
for their ability to protect lethally irradi-
ated mice from radiation death. Spleen
cells treated with 0-25 ,tg/ml DNFB were
unable to protect irradiated mice, while
spleen cells treated with 0-025 jtg/ml
DNFB were as capable of this function
as control spleen cells (Table IV). The
DNP sites/cell showed excellent correla-
tion between the two parameters; with
each tenfold dilution of DNFB during
cell exposure, there was a 1 log decrement
in the ability of the DNP-tumour cells
to inhibit the ABC of the anti-DNP anti-
serum (Fig. 1). The amount of DNP on
tumour cells exposed to 0-25 4ag/ml
DNFB approached a maximum, since a
fortyfold increase in DNFB concentration
resulted in little or no increase in the
number of DNP sites/cell (Table V).
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TABLE V.-Amount of DNP Coupled to
Tumour Cells at Various DNFB Concen-
trations
DNFB
concentration
Experiment (GLg/ml)
I . 10
II
III
DNP sites
Cell*
5-7x 104
0-5 . 7-1x104
0-25 74x 104
0-25 6-9x104
0-025 . 3-1x105
* Expressed as the concentration of DNFB-
treated cells required to yield 50% inhibition of the
ABC of anti-DNP antiserum.
In order to avoid saturation of the
tumour cell membrane by DNP, and so
render other cell surface antigens inactive
or inaccessible. we chose 0-025 ,ug/ml as
the concentration ofDNFB during tumour
cell dinitrophenylation for the following
experiment. Control or DNP-tumour cells
were exposed to 5000 rad in vitro to
render them incapable of tumour forma-
tion. They were then injected i.p. into
separate groups of control, DNFB skin-
painted, or DNP6 CGG-immunized mice.
Ten days later these mice, together with
appropriate control unimmunized animals,
were challenged with varying numbers of
viable tumour cells and subsequently
examined for tumour formation. Al-
though earlier studies (Table VI; experi-
ment I) has shown diminished tumour
formation in control animals immunized
with x-ray-killed tumour cells, in this
experiment, immunization with neither
x-ray-killed tumour cells nor x-ray-killed
DNP-tumour cells resulted in significant
protection against subsequent tumour
formation when the animals were chal-
lenged with viable tumour cells, regardless
of whether or not the animal had pre-
viously been exposed to the hapten
(Table VI; experiment II). In another
experiment (not shown), control, DNFB-
TABLE VI.-Effect ofPre-immunization with X-ray-killed Control or
DNP-coated Tumour Cells on Subsequent Tumour Growth
Number of tumour Mice immunized with 107
cells injected s.c. Control mice x-ray-killed tumour cells i.p.
Experiment I
107 .
106 .
105 .
104
103 .
Pre-immunization
Experiment II
None
107 x-ray-killed DNP
tumour cells i.p.
107 x-ray-killed tumour
cells i.p.
10/10*
10/10
10/10
7/10
7/10
Number of
tumour cells
injected s.c.
107
106
105
104
103
107
106
105
104
103
107
106
105
104
103
Control
mice
10/10
10/10
10/10
3/10
1/7
10/10
9/10
7/10
4/10
1/10
9/10
10/10
8/10
3/10
0/10
10/10
9/10
6/10
2/10
1/11
DNFB skin DNP-CGG
sensitized immunized
mice mice
* Number of tumours observed/number of mice/group.
7
10/10
10/10
9/10
3/10
0/10
9/10
7/10
7/10
2/10
0/9
10/10
9/10
2/10
1/10
0/10
10/1-0
10/10
9/10
4/10
0/7
10/10
10/10
10/10
3/10
0/10
10/10
8/10
4/10
1/10
0/11
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skin-painted, or DNP6 CGG-immunized
mice were challenged s.c. with graded
numbers of viable, non-irradiated DNP
tumour cells.* Prior host exposure to
the hapten did not inhibit the formation
of tumours by the challenge inoculum.
The effective tyrosylation of tumour
cells was established by agglutination of
the hapten-treated cells using anti poly-
L-tyrosyl serum. Positive reaction between
the cells exposed to 1 mg anhydride per
108 cells and the antiserum was observed
at 1/128 dilution of the serum; cells
treated with 10 mg anhydride per 108
cells were agglutinated by an antiserum
dilution of 1/256.
The tyrosylation of tumour cells did
not greatly diminish their viability, as
measured by the trypan blue dye exclu-
sion test (Table VII). There was no
significant change in the presence of
H-2 antigens on dioxane-treated or tyro-
TABLE VII.-Effect of Tyrosylation and
Dioxane Treatment on Trypan Blue
Viability of Tumour Cells
Treatment
Tyrosine Tyrosine
(1 mg/108 (10mg/108
Control Dioxane cells) cells)
Trypan
blue
viability
(%) 89
sylated cells as compared to control
tumour cells, according to the anti-
globulin test (Table VIII).
The ability of tyrosylated tumour
cells to induce subcutaneous tumours was
reduced to approximately 1/100 of control
values when 10 mg of tyrosine per 108
cells was used, and to 1/1000 of control
values when absolute dioxane or 1 mg
of tyrosine per 108 was used (Table IX).
The effect of pre-immunization of
mice with tyrosylated cells on subsequent
tumour growth was investigated. Con-
trol, tyrosylated, and dioxane-treated
tumour cells were exposed to 5000 rad
in vitro and injected into different groups
TABLE X.-Effect of Pre-immunization
with Tyrosylated Cells on Subsequent
Tumour Growth
Number of tumour
cells injected s.c.
Pre-immunization
None
107 x-ray-killed tumour cells
107 x-ray-killed tyrosylated
(1 mg/108 cells) tumour
cells
107 x-ray-killed tyrosylated
(10 mg/108 cells) tumour
cells
107 x-ray-killed dioxane
treated tumour cells
104 105
5/9* 6/8
1/9 4/8
5/9
106
9/9
6/9
5/8 8/9
3/9 6/8 9/9
9/9 8/8 9/9
* Number of mice with tumour/number of mice
80 82 71 injected.
TABLE VIII.-Effect of Tyrosylation on
Antiserum Control tumour Dioxane trE
dilution cells tumour c
1/4 . 1 * 84* . 1 *80
1/16 . 1-*26 . 1 *67
eated
bells
Tyrosylated cells Tyrosylated cells
(1 mg/108 cells) (10 mg/108 cells)
2-4 . 1-57
1-96 . 1-80
* Absorption ratio:
Counts with anti CBA serum
Counts with normal serum at the same dilution
TABLE IX.-Tumour Formation by Control and Tyrosylated Tumour Cells
Number of cells Tyrosine Tyrosine
injected Control Dioxane (1 mg/108 cells) (10 mg/108 cells)
107 ' N.D. 4/10 5/10 9/10
106 . 8/8* . 0/8 . 0/8 . 3/8
105 . 8/8 . 0/8 . 0/8 0/8
104 b6/8 0/8 0/8 0/8
*Number of tumours observed/number of mice/group.
* Dinitrophenylation by exposure to 0 025 ,ug/ml DNFB.
Antiglobulin Test with Anti H-2 Serum
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of mice as described earlier. Although
immunization with x-ray-killed tumour
cells resulted in diminished tumour forma-
tion, immunization with dioxane-treated
or tyrosylated tumour cells did not
prevent tumour formation (Table X).
DISCUSSION
Our attempts to enhance rejection of
tumour cells by pre-immunization with
hapten-coated cells were unsuccessful.
This was not the result of decreased cell
viability, since this factor was not affected
by DNP attachment, nor does it seem
to be due to the loss of antigens from the
cell surface, as can be judged from the
antiglobulin test performed with tyro-
sylated cells (Table VIII). Loss of some
antigenic determinants, not necessarily
H-2 antigens, however, cannot be
excluded, since the ability of TYR cells to
produce tumours in mice was drastically
diminished. It may be that different
methods of immunization are necessary
for the enhancement of immunogenicity.
Studies on the ability of the coupling
of DNP to mouse tumour cells to enhance
immunogenicity in syngeneic recipients
have been reported recently by Martin
et al. (1971), whose studies differed from
ours in that the DNP was coupled to
cell surfaces in the form of 2-4 dinitro-
phenylaminocaproate. In addition, they
made no attempt to investigate the
viability of hapten-coupled cells or to
assess the effect of hapten concentration
on cell membranes on the immuno-
genicity oftumour cells. The latter point
is of particular importance, since Wolf
has shown that immunogenic tumour cells
are no longer capable of protecting mice
from subsequent challenge with viable
tumour cells if the immunizing cells have
been heavily coated with DNP (Wolf
et al., 1970). Nevertheless, Martin et al.
(1971) were able to detect slightly but
significantly increased cell mediated cyto-
toxicity for native tumour cells in the
spleens of animals immunized with DNP-
coated cells. They did not investigate
whether such in vitro evidence ofimmunity
in DNP-tumour cell immunized animals
correlated with an increased ability of
such mice to reject tumours in vivo.
Thus, although our results are at variance
with theirs, the difference may simply
reflect the discrepancy between the
methods employed. Ultimately, however,
the significance of any similar attempts
to enhance the rejection of tumour cells
by pre-immunization with hapten-coated
cells will be best established by evidence
of an in vivo expression of the immune
state.
The fact that exposure of both tumour
cells and normal spleen cells to DNFB
yielded cells that were comparable both
in the number of DNP molecules coupled,
and in the subsequent viability of the
DNP-coated cells, suggests that the effects
of DNFB on tumour cells is not unique
to special membrane adaptations related
to their oncogenic properties. The
methods of hapten attachment which we
have described may be of value to other
workers interested in pursuing this prob-
lem.
The authors are grateful to Professor
N. A. Mitchison for valuable advice and
criticism.
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